Literature DB >> 16370474

[Treatment of erysipelas in Germany and Austria--results of a survey in German and Austrian dermatological clinics].

Sabine Brennecke1, Martin Hartmann, Helmut Schöfer, Heinrich Rasokat, Erwin Tschachler, Norbert H Brockmeyer.   

Abstract

BACKGROUND: Erysipelas is a severe soft tissue infection usually caused by streptococci. The infection is restricted to the dermis and subcutaneous tissues. Treatment with antibiotics is essential. Many different therapeutic regimens are recommended, based mainly on empirical data and only partly proven by clinical studies.
MATERIAL AND METHODS: Our aim was to evaluate the treatment of erysipelas in Germany and Austria by means of a questionnaire and to derive treatment recommendations from this data. RESULTS AND
CONCLUSION: The majority of clinics treat patients with erysipelas as inpatients with intravenous antibiotics. The usual first line treatment is group G penicillin (80%). Other choices include amino-penicillins (11%), cephalosporins (16.5%) and anti-staphylococcal penicillins (6.9%) are used. As second line antibiotics macrolides (63.5%), clindamycin (52.5%), penicillins (18.5%), cephalosporins (40%) and fluoroquinolones (20.5%) are mentioned. Carbapenems, tetracyclines, nitroimidazoles, glycopeptides, aminoglycosides, cotrimoxazole, fusidic acid and fosfomycin are used rarely. The median treatment duration is 10 days. Adjuvant measures are anticoagulation, non-steroidal anti-inflammatory agents, dressings, immobilization and treatment of local predisposing factors such as interdigital tinea.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16370474     DOI: 10.1111/j.1610-0387.2005.04799.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  1 in total

1.  Risk factors of recurrent erysipelas in adult Chinese patients: a prospective cohort study.

Authors:  Ang Li; Ni Wang; Lingzhi Ge; Hongyan Xin; Wenfei Li
Journal:  BMC Infect Dis       Date:  2021-01-07       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.